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INTRODUCTION 
Mental retardation is age old problem. Mental 
retardation is still elusive to researchers due to 
multidimensionality of psychological, medical, 
educational and social aspects, which alters mental 
functions and capability. Thorough evaluation and 
understanding is necessary to minimize its curb on 
health of individual, society and nation. 
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Definition of Mental retardation based on mental sub-
capability. According to the American Association on 
Mental Retardation (AAMR), Mental retardation is a 
disability characterized by significant limitations both 
in intellectual functioning and in adaptive behavior as 
expressed in conceptual, social, and practical adaptive 
skills. This disability originates before age 18.
[1]
 
According to WHO - ICD-10 guide for Mental 
Retardation - Mental retardation is a condition of 
arrested or incomplete development of the mind, 
which is especially characterized by impairment of 
skills manifested during the developmental period, 
which contribute to the overall level of intelligence, 
i.e., cognitive, language, motor and social abilities.
[2]
 
Mental sub capability is divided in 4 categories. Mild 
(50 IQ to 69 IQ, Educable), Moderate (35 – 49 IQ, 
Trainable), Severe (20 – 34 IQ) and Profound (Below 
20 IQ).
[3]
  
Prevalence of mental retardation is - Peak among 10-
14 years age group (due to late detection) - 85% of all 
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Mental retardation is still elusive to researchers due to multidimensionality of psychological, medical, 
educational and social aspects, which alters mental functions and capability. Mental sub capability 
divided in 4 categories, Mild, Moderate, Severe and Profound. Chief aim of management of mental 
retardation is to make child more capable of performing common activities of everyday life by positive 
improvement in mental sub-capability. Mental retardation required multidimensional management 
approach. Present study focused on medicinal intervention, particularly analysis of comparative 
effectiveness of selected drug formulations (Astamangalghrita and Jyotismatitaila) from classical text 
of Ayurveda. Study design with the aims to compare the effectiveness of Jyotismatitaila and 
Astamangal Ghrita Nasya on Mental retardation. Assessment were based on Mental Status Score and 
IQ score taken before starting of treatment and after completion of treatment in both group. Obtained 
data was analyzed statistically. In this study, from result we conclude that both drugs are effective to 
improve Mental Status parameter and in IQ, but higher percentage and significance wise Jyotismati 
Taila had better result than Astamangal Ghrita Nasya.  
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MR comes under mild degree of MR – ratio of 
occurrence in Males to Females is  1.6 to 1 - found 
Higher number in low socioeconomic classes.
[4]
 
Chief aim of management of mental retardation is to 
make child more capable of performing common 
activities of everyday life by positive improvement in 
mental sub-capability.
[5],[6],[7]
 
Mental retardation required multidimensional 
management approach, which classified in - 
preventive and specific measurements.  
Prevention include from genetic counseling to 
prevention during ante-peri-post natal condition and 
care and support and education during childhood.  
While specific measures include special education to 
child, physiotherapy, speech therapy, counselling, 
occupational therapy, medicinal intervention etc.  
Present study focused on medicinal intervention, 
particularly analysis of comparative effectiveness of 
selected drug formulations from classical text of 
Ayurveda. 
In Ayurveda, there are ample evidence of many 
nootropic drugs uses for improvement and 
enhancement of mental sub-capability, two 
formulation were selected for the study are 
Ashtamangala Ghrita
[8],[9],[10] 
and Jyotismati 
Taila.
[11],[12]
 There are numerous study available on 
effect of Astamangal Ghrita
[13],[14]
 in oral mode of 
administration. So this study taken up Nasya (Nasal 
route) as a mode of administration for Astamangal 
Ghrita, while Jyotismati Taila given oral route. 
OBJECTIVES OF THE STUDY 
To compare the effectiveness of Jyotismati Taila and 
Astamangala Ghrita Nasya on Mental retardation 
MATERIALS AND METHODS 
Study design 
The patients for the study were selected from OPD 
and IPD of Kaumarbhritya Dept., IPGT and RA, 
Jamnagar. Patients were enrolled after they satisfy 
the inclusion/exclusion criteria, randomly distributed 
in Group A and Group J, detailed assessment carried 
out before starting of therapy and after completion of 
therapy. Obtained data analyze statistically. 
Criteria for the selection of patients 
Inclusion Criteria  
 Either sex 
 Age between 5 years – 16 years. 
 Having Mental sub-capability 
Exclusion Criteria 
 Congenital anomalies or deformities 
 Having any serious illness 
 Profound degree of Mental retardation 
Group 
Patients were randomly distributed in 2 group 
 Group A : Astamangal Ghrita Nasya 
 Group J : Jyotismati Taila 
Posology 
 Astamangal Ghrita(as Nasya) - instill 6-8 drops 
according to age in morning - administer 1 week 
with 1 week gap  for 2 months. 
 Jyotismati Taila (given Orally - mix in milk) - 2 to 
10 drops according to age in morning for 2 
months. 
Criteria for Assessment 
Assessment were based on Mental Status Score and 
IQ score (by S. Shukla-1976)
[15]
 taken before starting 
of treatment and after completion of treatment in 
both group.  
Criteria for Assessing Total Effect 
After completion of the treatment given to the 
patients of Group A, Group J of mental retardation 
were finally assessed and evaluated in terms of cured, 
markedly improved, moderately improved, improved 
and unchanged. The same procedure or methods of 
assessment and evaluation was applied to the 
patients of both group of studies.  
Results 
Table 1: Patients completed the study 
 Group A Group J Total % 
Borderline 5 3 8 30.77 
Mild 3 6 9 34.62 
Moderate 2 3 5 19.23 
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Severe 2 2 4 15.38 
Table 2: Effect of therapies on Mental Status 
 Mental status Group A Group J 
Attention 53.85%↑(M-0.59, 
SE-0.148, T-
3.924)** 
80 %↑ (M-0.86, SE-
0.097, T-8.831)*** 
Behavior 69.23%↑ (M-0.75, 
SE-0.179, T-
4.179)** 
56.25 %↑(M-0.75, 
SE-0.132, T-
4.857)*** 
Concentration 63.64 %↑(M-0.58, 
SE-0.148, T-
3.924)** 
81.25 %↑ (M-0.93 , 
SE-0.071, T-13)** 
Consciousness 43.75 %↑ (M-0.69, 
SE-0.148, T-
3.924)** 
81.25 %↑ (M-0.93, 
SE-0.071, T-13)*** 
Communication 25 %↑ (M-0.41, 
SE-0.148, T-
2.803)* 
64.71%↑ (M-0.79, 
SE-0.113, T-
6.904)*** 
Emotions 64.29% ↑(M-0.75, 
SE-0.179, T-
4.179)** 
60 %↑ (M-0.04, SE-
0.132, T-4.837)*** 
Information 21.05 %↑(M-0.34, 
SE-0.142, T-
2.345)* 
64.29 %↑ (M-0.64, 
SE-0.132, T-
4.837)*** 
Judgments 55 %↑ (M-0.58, 
SE-0.148, T-
3.924)** 
92.31 %↑(M-0.86, 
SE-0.097, T-
8.831)*** 
Orientation  42.86 %↑ (M-0.5, 
SE-0.15, T-
3.316)** 
64.29 %↑ (M-0.64, 
SE-0.132, T-
4.837)** 
Perception  46.67 %↑(M-0.58, 
SE-0.148, T-
3.924)** 
84.62 %↑ (M-0.78, 
SE-0.113, T-
6.904)*** 
Thinking  37.5 %↑ (M-0.5, 
SE-0.15, T-
3.316)** 
69.23 %↑ (M-0.64, 
SE-0.132, T-
4.837)** 
Data: ↓ = Decrease, ↑=Increase, * P<0.05, **P<0.01, 
***P<0.001  
Table 3: Effect of therapies on Memory 
Memory Group A Group J 
Immediate 
Memory 
90.91 % ↑ (M-
0.389, SE-0.112, T-
7.416 )*** 
130.77 %↑ (M-
0.425, SE-0.113, T-
16.67)*** 
Recent 
Memory  
76.92 %↑ (M-0.389, 
SE-0.112, T-
7.416)*** 
130 % ↑ (M-0.267, 
SE-0.071, T-13)*** 
Remote 
Memory  
58.33 %↑ (M-0.514, 
SE-0.148, T-3.924)* 
122.22 %↑(M-
0.425, SE-0.113, T-
6.904)** 
Data:, ↓ = Decrease, ↑=Increase, * P<0.05, **P<0.01, 
***P<0.001  
Table 4 : Effect of therapies on IQ 
 IQ Group A Group J 
Total IQ 8.5 % ↑ (M-5.39, SE-
0.937, T-5.752 )*** 
12.41 %↑ (M-6.94, SE-
0.527, T-13.156)*** 
Borderline 
IQ 
8.37 %↑ (M-6.9, SE-
1.951, T-3.536)* 
10.21 % ↑ (M-7.82, SE-
0.962, T-8.125)* 
Mild IQ 7.53 %↑ (M-4.86, SE-
0.511, T-9.507)* 
10.21 %↑(M-6.23, SE-
1.12, T-5.006)** 
Moderate 
IQ 
8.67 %↑ (M-4.32, SE-
2.655, T-1.629) 
15.88 % ↑(M-7.42, SE-
0.378, T-19.602)** 
Severe IQ 8.97%↑ (M-3.51, SE-
1.030, T-3.407) 
30.61 % ↑ (M-7.06, SE-
0.505, T-13.970)* 
Data:, ↓ = Decrease, ↑=Increase, * P<0.05, **P<0.01, 
***P<0.001  
Table 5: Overall Effect of therapies  
 Overall effect Group A Group J 
Markedly improved 41.66 % 21.43 % 
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Moderately improved 16.67 % 7.14 % 
Improved  25 % 57.14 % 
Overall improvement 83.33% 85.71% 
Unchanged 16.67 % 14.29 % 
 In the present study, registered 26 patients 
randomly distributed in Group A – 12 patients and 
Group J – 14 patients, categorized under 
Borderline (8 patients-30.77%), Mild (8 patients-
34.62%), Moderate (5 patients - 19.23) and Severe 
(4 patients - 15.38) degree of Mental retardation 
 In observational result found most of pts 
belonging to the age group of 9-12 years 
(57.14%), males (71.43%), middle socio-eco status 
(60%) and all were from urban habitat. These data 
fall in lines of international prevalence rate among 
age group, male-female ratio and predominance 
of mental retardation in lower and middle socio-
economical Status. 
 Abnormal social behaviour (77.14%), delayed 
milestone (68.57%), impaired memory / slow 
learning (100%) and speech defect (40%) were 
observed as primary sign and symptoms in the 
present study. Convulsion (31.43%) and bed 
wetting (48.57%) were observed as dominant 
associated symptoms in patients. 
DISCUSSION 
Comparative effect of therapies on Mental 
Retardation  
Effect of therapies on Mental Status 
In comparison of Group A  and Group J, Group A 
provided better relief and significantly improve 
behaviour (69.23%) and emotions (64.29%), while rest 
of other Mental Status parameter showed better 
result with Group J with highly significance. (table 2) 
Effect of therapies on Memory 
Group J had better improvement with highly 
significant result in all 3 types of memory in term of 
improvement in immediate memory (130.77%), 
recent memory (130%), remote memory (122.22%). 
Group A also had good result to increase Memory of 
all type but less in percentage compare to group J. 
(table 3) 
Effect of therapies on IQ 
Group J had better improvement with highly 
significant result in all 4 categories of IQ in mental 
retardation i.e., total IQ (12.41%), borderline IQ 
(10.21%), mild IQ (10.21%), moderate IQ (15.88%) and 
in severe categories IQ (30.61%). Group A also 
showed good result to increase IQ but less in 
percentage compare to group J. In moderate and 
severe categories only Group J showed significant 
result. (table 4) 
Overall effect of therapies 
In comparison of overall effect, group A achieve 
better result in markedly and moderately 
improvement, but overall improvement (markedly 
improve, moderately improve and improve) is better 
in Group J. (table 5) 
Nootropic effect of Ashtamangal Ghrita and 
Jyotismati Taila is well established in Ayurveda. Both 
drugs having potency of improving intellect, improves 
memory recall power and retention span thereby 
memory enhancer action, induces alertness, improves 
concentration, reduces rate of cell death of neurons, 
improves ability of thinking and reasoning and 
improves concentration, alertness, and other 
cognitive functions.
[16]-[21]
 In present study, both the 
drugs proves nootropic effect with assessing Mental 
status and IQ parameters. But possibly Jyotismati (the 
natural luminosity (Jyoti) of the mind (Mati) having 
advantage of nervine stimulant and neuroprotective 
effect
[21]
 in compare to Ashtamangal Ghrita, reflected 
in higher percentage and more significant in 
Jyotismati Taila group. Result of comparative effect of 
therapy also reflect that study with combine therapy 
of both drugs need to be evaluated for overall more 
beneficial effect to manage Mental retardation. 
CONCLUSION 
In this study of mental retardation found most of 
patients were belonging to the age group of 9-12 
years, males, and all were from urban habitat. 
Children of lower and middle income groups were 
observed more affected in comparison to children 
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belonging to higher income group. The delayed cry, 
neonatal diseases were also noticed in some of the 
patients. Delayed milestone, abnormal social 
behavior, impaired/slow learning, convulsions, 
enuresis observed in majority of patients. In 
comparison of both drugs, Astamangala Ghrita Nasya 
is better therapy for improvement in behavior and 
emotion parameter of mental status, while Jyotismati 
Taila is better in rest of all mental status parameter. 
Astamangala Ghrita Nasya and Jyotismati Taila both 
were better in improvement in all type of memory 
and IQ in all category, but higher percentage of 
improvement was found with Jyotismati Taila group. 
In comparison of overall effect, Astamangal Ghrita 
Nasya achieve better result in markedly and 
moderately improvement, but total improvement 
(markedly improve, moderately improve and improve) 
is better in Jyotismati Taila. In present comparative 
study both drug was proved their efficacy with good 
result. In future, combine therapy of these drug need 
to evaluate to cover all aspect of Mental retardation. 
Present scientific study has been proved satisfactorily 
with significant result, even then period of this study 
may be extended to find out the minute efficacy of 
the drugs in order to standardize the parameters 
adopted in existing scientific work. 
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